RESPIRATORY INHALERS MARKET ANALYSIS

Respiratory Inhalers Market, By Type (Manually Operated and Digitally Operated), By Product (Dry Powder Inhaler, Metered Dose Inhaler, Others), By Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Arterial Hypertension, Other), By End User (Hospitals & Clinics, Respiratory Care Center, Academic and Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In June 2024,Boehringer Ingelheim,Pharmaceutical company has launched a new program that caps out-of-pocket costs at US$35 per month for eligible patients using the company's inhalers. This initiative aims to make Boehringer inhalers more affordable for patients who have struggled with the current healthcare system.
In April 2024,Teva Pharmaceutical Industries Ltd. and Launch Therapeutics, Inc. have entered into a clinical collaboration to advance the research of Teva’s ICS-SABA (TEV-‘248)For adult and pediatric asthma purposes, Teva's TEV-'248 may be the first Dual-Action Asthma Rescue Inhaler to combine an Inhaled Corticosteroid with a Short-Acting Beta-Agonist (ICS-SABA).
In September 2020, Teva Respiratory, LLC, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has launched AirDuo Digihaler (fluticasone propionate and salmeterol) and ArmonAir Digihaler (fluticasone propionate), two new digital inhalers for asthma maintenance. AirDuo is used to control and prevent asthma symptoms in individuals 12 and older, while ArmonAir is for long-term asthma treatment in the same age group.
In February 2022, AstraZeneca and Honeywell are collaborating to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% lower Global Warming Potential (GWP) compared to current propellants. This announcement aligns with AstraZeneca’s Sustainability Report, highlighting its progress on the Ambition Zero Carbon program.